鄰近類別 專利 [0/18] 期刊論文 [157/157] 類別統計 近3年內發表的文件:0(0.00%) 含全文筆數:23(62.16%) 文件下載次數統計 下載大於0次:23(100.00%) 下載大於100次:23(100.00%) 檔案下載總次數:12736(13.06%) 最後更新時間: 2024-12-01 03:45 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Targeting RSPO3 reduces stem cell f... BPR6K609: An Aurora kinase inhibito... Inhibition of Rspo-Wnt pathway faci... An Aurora kinase inhibitor BPR6K471... BPRDP056, a novel small molecule dr... Use of integrated genomic analyses ... 4-Bromophenylhydrazinyl benzenesulf... Targeting RSPO3 reduces stem cell f... Study of glioblastoma multiforme me... Optimization of quinazoline-based k...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-25 / 37. (共2頁) 1 2 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2020-08	BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification	Cancer Research. 2020 Aug;80(16):1937.
2019-10	Inhibition of Rspo-Wnt pathway facilitates checkpoint blockade therapy by anti-RSPO3 antibody (DBPR117)	Annals of Oncology. 2019 Oct;30(Suppl. 5):191.
2019-07	BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy	Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 227.
2019-07	Use of integrated genomic analyses in patient-derived tumor model to discover new clinical indications for the multikinase inhibitor drug candidate, DBPR216	Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 4626.
2019-07	An Aurora kinase inhibitor BPR6K471 inhibits tumor growth and reduces the cancer stem cell-like properties of small cell lung cancer	Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 3851.
2018-12	Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer	Cancer Science. 2018 Dec;109(SI, Suppl. 2):210.
2018-12	Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer	Cancer Science. 2018 Dec;109(Suppl. 2, SI):1257.
2018-07	4-Bromophenylhydrazinyl benzenesulfonylphenylureas inhibit indoleamine 2,3-dioxygenase in vitro and in vivo	Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 1664.
2018-01	Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer	Cancer Science. 2018 Jan;109(Suppl. 1):739.
2017-04	Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation	Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482.
2016-12	Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P.
2016-10	Multifunctional nanoparticles for oral protein drug delivery	Diabetes Research and Clinical Practice. 2016 Oct;120(Suppl. 1):S19.
2016-08	Dipeptidyl peptidase-4 inhibitor LAF-237 improves glucose tolerance and expends graft beta cell mass in diabetic mice transplanted with a sufficient number of islets	Diabetologia. 2016 Aug;59(Suppl. 1):S198.
2016-02	Multifunctional nanoparticles for oral protein drug delivery	Nanomedicine: Nanotechnology, Biology and Medicine. 2016 Feb;12(2):463.
2015-08	Zinc-dipicolylamine directed pharmaceutical delivery system (ZAPS) as an innovative cancer drug delivery platform	Cancer Research. 2015 Aug;75(Suppl. 15):Abstract number 4413.
2015-08	Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia	Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490.
2014-11	Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent	European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93.
2014-10	YYEI motif is critical to oncogenicity of 14-3-3 proteins	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 3527.
2014-10	Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756.
2014-03	DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study	Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
2013-11	A development drug candidate targeting EGFR kinase for lung cancer: DBPR112	Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780.
2013-04-07	BPR000K, a novel Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI.
2013-04-07	Development drug candidate targeting EGFR kinase: DBPR112	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI.
2013-04	Design and synthesis of Aurora kinase inhibitors as anticancer agents	Abstracts of Papers - American Chemical Society. 2013 Apr;245:Article number 301-MEDI.
2012-11	BPR1J271, a novel FLT3 inhibitor for treating acute myeloid leukemia	European Journal of Cancer. 2012 Nov;48(Suppl. 6):53-54.

顯示項目1-25 / 37. (共2頁) 1 2 > >> 每頁顯示[10|25|50]項目